Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.91% | -4.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.91% | -4.06% | |||
| Cost of Revenue | 10.65% | 15.13% | |||
| Gross Profit | -5.77% | -19.13% | |||
| SG&A Expenses | -29.44% | 10.05% | |||
| Depreciation & Amortization | -4.74% | -8.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.57% | 8.74% | |||
| Operating Income | 35.17% | -24.61% | |||
| Income Before Tax | 37.16% | -35.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.16% | -35.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.16% | -35.74% | |||
| EBIT | 35.17% | -24.61% | |||
| EBITDA | 38.66% | -28.45% | |||
| EPS Basic | 38.71% | 15.07% | |||
| Normalized Basic EPS | 41.03% | 15.22% | |||
| EPS Diluted | 38.71% | 15.07% | |||
| Normalized Diluted EPS | 41.03% | 15.22% | |||
| Average Basic Shares Outstanding | 3.88% | 59.51% | |||
| Average Diluted Shares Outstanding | 3.88% | 59.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||